239 related articles for article (PubMed ID: 9166489)
21. Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter phase II trial.
Greco FA; Hainsworth JD
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-14-S12-17. PubMed ID: 9331113
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
23. Phase I clinical and pharmacokinetic study of taxol.
Wiernik PH; Schwartz EL; Strauman JJ; Dutcher JP; Lipton RB; Paietta E
Cancer Res; 1987 May; 47(9):2486-93. PubMed ID: 2882837
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of taxol administered as a short i.v. infusion daily for 5 days.
Grem JL; Tutsch KD; Simon KJ; Alberti DB; Willson JK; Tormey DC; Swaminathan S; Trump DL
Cancer Treat Rep; 1987 Dec; 71(12):1179-84. PubMed ID: 2891442
[TBL] [Abstract][Full Text] [Related]
25. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II study of paclitaxel and radiotherapy in non-small cell lung cancer.
Marangolo M; Emiliani E; Rosti G; Giannini M; Vertogen B; Zumaglini F
Semin Oncol; 1996 Dec; 23(6 Suppl 16):124-7. PubMed ID: 9007139
[TBL] [Abstract][Full Text] [Related]
28. Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial.
Akerley W; Choy H; Safran H; Sikov W; Rege V; Sambandam S; Wittels E
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-10-S12-13. PubMed ID: 9331112
[TBL] [Abstract][Full Text] [Related]
29. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
30. Paclitaxel via 1-hour infusion: rationale and pharmacology.
Greco FA; Hainsworth JD
Semin Oncol; 1996 Dec; 23(6 Suppl 15):19-20. PubMed ID: 8996592
[TBL] [Abstract][Full Text] [Related]
31. [Phase I study of paclitaxel].
Horikoshi N; Inoue K; Aiba K; Mukaiyama T; Ogihara A; Sumida T; Akatsuka Y; Besho A; Inamoto Y; Uchida T
Gan To Kagaku Ryoho; 1994 Oct; 21(14):2407-14. PubMed ID: 7944484
[TBL] [Abstract][Full Text] [Related]
32. Activity of JM9 in advanced ovarian cancer: a phase I-II trial.
Bramwell VH; Crowther D; O'Malley S; Swindell R; Johnson R; Cooper EH; Thatcher N; Howell A
Cancer Treat Rep; 1985 Apr; 69(4):409-16. PubMed ID: 3995511
[TBL] [Abstract][Full Text] [Related]
33. [Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion].
Noda K; Ikeda M; Kudo R; Nishiya I; Yajima A; Tanaka K; Kodama S; Takahashi T; Tokunaga A; Satoh I; Nozawa S; Taketani Y; Terashima Y; Isonishi S; Takeda Y; Nishijima M; Kuroshima Y; Fujii S; Izumi R; Tamaya T; Mori T; Okada H; Ogita S; Ozaki M; Hatae M
Gan To Kagaku Ryoho; 1996 Feb; 23(3):317-25. PubMed ID: 8712825
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.
Young CW; Fanucchi MP; Declan Walsh T; Baltzer L; Yaldaei S; Stevens YW; Gordon C; Tong W; Rifkind RA; Marks PA
Cancer Res; 1988 Dec; 48(24 Pt 1):7304-9. PubMed ID: 3191501
[TBL] [Abstract][Full Text] [Related]
35. Phase I clinical and pharmacological study of merbarone.
Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
[TBL] [Abstract][Full Text] [Related]
36. A feasibility study of 1-h paclitaxel infusion in patients with solid tumors.
Tsavaris N; Polyzos A; Kosmas C; Giannikos L; Gogas J
Cancer Chemother Pharmacol; 1997; 40(4):353-7. PubMed ID: 9225955
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of taxol given as a 3-hour infusion every 21 days.
Kris MG; O'Connell JP; Gralla RJ; Wertheim MS; Parente RM; Schiff PB; Young CW
Cancer Treat Rep; 1986 May; 70(5):605-7. PubMed ID: 2871928
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
Seidman AD; Tiersten A; Hudis C; Gollub M; Barrett S; Yao TJ; Lepore J; Gilewski T; Currie V; Crown J
J Clin Oncol; 1995 Oct; 13(10):2575-81. PubMed ID: 7595709
[TBL] [Abstract][Full Text] [Related]
39. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.
Burris H; Irvin R; Kuhn J; Kalter S; Smith L; Shaffer D; Fields S; Weiss G; Eckardt J; Rodriguez G
J Clin Oncol; 1993 May; 11(5):950-8. PubMed ID: 8098059
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
J Clin Oncol; 1994 Feb; 12(2):241-8. PubMed ID: 7509380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
